In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine

Journal of the National Cancer Institute

Volumn 102, Issue 11, 2010, Pages 758-770

  Li, Zhijie ^a   Tan, Fei ^a   Liewehr, David J ^a   Steinberg, Seth M ^a   Thiele, Carol J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; MITOGEN ACTIVATED PROTEIN KINASE; PERIFOSINE; PROTEIN KINASE B; S6 KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KAPLAN MEIER METHOD; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TUMOR VOLUME; TUMOR XENOGRAFT;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CELL SURVIVAL; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; GROWTH INHIBITORS; HUMANS; KAPLAN-MEIERS ESTIMATE; LUCIFERASES; LUMINESCENT AGENTS; MICE; MUTATION; NEUROBLASTOMA; NIH 3T3 CELLS; PHOSPHORYLATION; PHOSPHORYLCHOLINE; PROTO-ONCOGENE PROTEINS C-AKT; TRANSPLANTATION, HETEROLOGOUS;

EID: 77953215965     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq125     Document Type: Article

References (59)

1. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11(8):1466-1477.
2. Stiller CA, Parkin DM. International variations in the incidence of neuro-blastoma. Int J Cancer. 1992;52(4):538-543.
3. Brodeur GM, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 5th ed. Philadelphia, PA: J B Lippincott Company; 2006:933-970.
4. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369(9579):2106-2120.
5. Mueller S, Matthay KK. Neuroblastoma: biology and staging. Curr Oncol Rep. 2009;11(6):431-438.
6. Caren H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifcations of the ALK gene in advanced sporadic neuroblastoma tumors. Biochem J. 2008;416(2):153-159.
7. Passoni L, Longo L, Collini P, et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res. 2009;69(18):7338-7346.
8. Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblas-toma cell line. Cancer Res. 2001;61(1):8-13.
9. Carr-Wilkinson J, O'Toole K, Wood KM, et al. High frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma. Clin Cancer Res. 2010;16(4):1108-1118.
10. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol. 1994;14(1):759-767.
11. Jones PF, Jakubowicz T, Hemmings BA. Molecular cloning of a second form of rac protein kinase. Cell Regul. 1991;2(12):1001-1009.
12. Opel D, Poremba C, Simon T, Debatin KM, Fulda S. Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res. 2007;67(2):735-745.
13. Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science. 1991;254(5029):274-277.
14. Gonzalez E, McGraw TE. The Akt kinase: isoform specifcity in metabolism and cancer. Cell Cycle. 2009;8(16):2502-2508.
15. Philp AJ, Campbell IG, Leet C, et al. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 2001;61(20):7426-7429.
16. Samuels Y, Diaz LA Jr., Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005;7(6):561-573.
17. Bellacosa A, Testa JR, Moore R, Larue L. A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities. Cancer Biol Ther. 2004;3(3):268-275.
18. Alkan S, Izban KF. Immunohistochemical localization of phosphorylated AKT in multiple myeloma. Blood. 2002;99(6):2278-2279.
19. Nakayama H, Ikebe T, Beppu M, Shirasuna K. High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer. 2001;92(12):3037-3044.
20. Porta C, Figlin RA. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3- kinase/Akt inhibitors. J Urol. 2009;182(6):2569-2577.
21. Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endo-metrial cancer. Endocr Relat Cancer. 2003;10(2):203-208.
22. Cicenas J. The potential role of Akt phosphorylation in human cancers. Int J Biol Markers. 2008;23(1):1-9.
23. Nakanishi K, Sakamoto M, Yamasaki S, Todo S, Hirohashi S. Akt phos-phorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer. 2005;103(2):307-312.
24. Nam SY, Lee HS, Jung GA, et al. Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis. APMIS. 2003;111(12):1105-1113.
25. Li Z, Jaboin J, Dennis PA, Thiele CJ. Genetic and pharmacologic identi-fcation of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death. Cancer Res. 2005;65(6):2070-2075.
26. George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008;455(7215): 975-978.
27. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature. 2008;455(7215):971-974.
28. Janoueix-Lerosey I, Lequin D, Brugières L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008;455(7215):967-970.
29. Mossé YP, Laudenslager M, Longo L, et al. Identifcation of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455(7215):930-935.
30. Vink SR, van Blitterswijk WJ, Schellens JH, Verheij M. Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy. Cancer Treat Rev. 2007;33(2):191-202.
31. Barnett SF, Bilodeau MT, Lindsley CW. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation. Curr Top Med Chem. 2005;5(2):109-125.
32. Patel V, Lahusen T, Sy T, Sausville EA, Gutkind JS, Senderowicz AM. Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res. 2002;62(5):1401-1409.
33. Richardson P, Lonial S, Jakubowiak A, et al. A multicenter phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM) [ASH annual meeting abstracts]. Blood. 2006;108:3582.
34. Chee KG, Longmate J, Quinn DI, et al. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer. 2007;5(7):433-437.
35. Leighl NB, Dent S, Clemons M, et al. A phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res Treat. 2008; 108(1):87-92.
36. Marsh Rde W, Rocha Lima CM, Levy DE, Mitchell EP, Rowland KM Jr, Benson AB III. A phase II trial of perifosine in locally advanced, unresect-able, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol. 2007; 30(1):26-31.
37. Bailey HH, Mahoney MR, Ettinger DS, et al. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer. 2006;107(10):2462-2467.
38. Argiris A, Cohen E, Karrison T, et al. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther. 2006;5(7):766-770.
39. Knowling M, Blackstein M, Tozer R, et al. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs. 2006;24(5):435-439.
40. Posadas EM, Gulley J, Arlen PM, et al. A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther. 2005;4(10): 1133-1137.
41. Ernst DS, Eisenhauer E, Wainman N, et al. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs. 2005;23(6):569-575.
42. Richardson P, Wolf J, Jakubowiak A, et al. Phase I/II results of a multi-center trial of perifosine (KRX-0401) + bortezomib in patients with relapsed or relapsed/refractory multiple myeloma who were previously relapsed from or refractory to bortezomib [ASH annual meeting abstracts]. Blood. 2008;112:870.
43. Cirstea D, Hideshima T, Pozzi S, et al. Combination of Nab-rapamycin and perifosine induces synergistic cytotoxicity and antitumor activity via autophagy and apoptosis in multiple myeloma (MM) [ASH annual meeting abstracts]. Blood. 2008;112:3663.
44. Jakubowiak A, Richardson P, Zimmerman TM, et al. Phase I results of perifosine (KRX-0401) in combination with lenalidomide and dexameth-asone in patients with relapsed or refractory multiple myeloma (MM) [ASH annual meeting abstracts]. Blood. 2008;112:3691.
45. Tazzari P, Papa V, Ricci F, et al. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myeloge-nous leukemia cells\a novel therapeutic approach for leukemia displaying elevated Akt signaling [ASH annual meeting abstracts]. Blood. 2008; 112:957.
46. Dasmahapatra GP, Didolkar P, Alley MC, Ghosh S, Sausville EA, Roy KK. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial ade-nocarcinoma cell lines. Clin Cancer Res. 2004;10(15):5242-5252.
47. Vink SR, Lagerwerf S, Mesman E, et al. Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts. Clin Cancer Res. 2006;12(5):1615-1622.
48. Crul M, Rosing H, de Klerk GJ, et al. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumors. Eur J Cancer. 2002;38(12):1615-1621.
49. Van Ummersen L, Binger K, Volkman J, et al. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res. 2004;10(22):7450-7456.
50. Floryk D, Thompson TC. Perifosine induces differentiation and cell death in prostate cancer cells. Cancer Lett. 2008;266(2):216-226.
51. Beppu K, Nakamura K, Linehan WM, Rapisarda A, Thiele CJ. Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer Res. 2005;65(11):4775-4781.
52. Jaboin J, Kim CJ, Kaplan DR, Thiele CJ. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3′-kinase pathway. Cancer Res. 2002;62(22):6756-6763.
53. Khanna C, Jaboin JJ, Drakos E, Tsokos M, Thiele CJ. Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis. In Vivo. 2002;16(2):77-85.
54. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotox-icity in human multiple myeloma cells. Blood. 2006;107(10):4053-4062.
55. Elrod HA, Lin YD, Yue P, et al. The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther. 2007; 6(7):2029-2038.
56. Engel JB, Honig A, Schönhals T, et al. Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphor-ylation. Eur J Obstet Gynecol Reprod Biol. 2008;141(1):64-69.
57. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplifcation of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224(4653):1121-1124.
58. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med. 1996;334(4):225-230. (Pubitemid 26030673)
59. Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolf PP, Manova-Todorova K, Holland EC. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblas-toma in vivo. Genes Dev. 2008;22(4):436-448.